- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/76 - Albumines
Détention brevets de la classe C07K 14/76
Brevets de cette classe: 389
Historique des publications depuis 10 ans
|
45
|
23
|
45
|
35
|
36
|
48
|
30
|
22
|
29
|
4
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| EpiVax, Inc. | 80 |
16 |
| Perfect Day, Inc. | 59 |
13 |
| Bioverativ Therapeutics Inc. | 213 |
11 |
| Neutrolis, Inc. | 29 |
10 |
| Zymeworks Inc. | 247 |
9 |
| Sanofi Aatd Inc. | 13 |
7 |
| CSL Behring GmbH | 345 |
6 |
| Mayo Foundation for Medical Education and Research | 3115 |
5 |
| Ablynx N.V. | 389 |
5 |
| Hamlet Pharma AB | 18 |
5 |
| Sartorius Albumedix Limited | 15 |
5 |
| Centre National de La Recherche Scientifique | 10102 |
4 |
| Massachusetts Institute of Technology | 9913 |
4 |
| The Brigham and Women's Hospital, Inc. | 2142 |
4 |
| Georgia State University Research Foundation, Inc. | 343 |
4 |
| Medicenna Therapeutics Inc. | 37 |
4 |
| Keros Therapeutics, Inc. | 61 |
4 |
| Invitria, Inc. | 39 |
4 |
| Novartis AG | 11254 |
3 |
| Bristol-myers Squibb Company | 4863 |
3 |
| Autres propriétaires | 263 |